Cardio-oncology is the multidisciplinary field concerned with cardiovascular health in people with cancer, from assessment before treatment through surveillance during therapy to the follow-up of long-term survivors. It encompasses the prevention and treatment of damage caused by drugs and radiation, management of pre-existing heart disease, and recognition of cardiovascular manifestations directly associated with the tumor. Its clinical objective is to reconcile the best available cancer care with preservation of cardiovascular function, through decisions proportionate to individual risk, anticancer benefit, and patient preferences.
Improved cancer survival has brought into sharper focus a problem that extends beyond chemotherapy-induced cardiomyopathy. Some events occur during treatment; others emerge years or decades after exposure, when patients may no longer be followed by oncology services. In an analysis of the US SEER registry involving more than 3.2 million people diagnosed with cancer between 1973 and 2012, 11.3% of the entire cohort died of cardiovascular causes during the observation period. This figure describes a heterogeneous historical population and does not represent the probability of cardiotoxicity from a contemporary treatment; nevertheless, it demonstrates the burden of cardiovascular disease throughout the lives of patients with cancer.
The frequency of injury varies according to the cancer, treatment, doses, duration of observation, and outcome definition: an increase in troponin, a change in strain, and heart failure requiring hospitalization are not equivalent events. The broader concept of cardiovascular toxicity includes myocardial, vascular, electrical, and pericardial disorders, whereas cardiac dysfunction denotes a more specific domain that can be recognized before symptoms appear. This distinction allows investigations and interventions to be selected according to the underlying mechanism.
Causes of cardiovascular disease in patients with cancer fall into three often overlapping groups: pre-existing cardiovascular disease, an effect of the malignancy, and treatment-related injury. Separating them is essential for causal assessment. Myocardial infarction during chemotherapy may result from pre-existing atherosclerosis, tumor-associated thrombosis, drug-induced vasospasm, or an imbalance between oxygen supply and demand during anemia or infection. Temporal sequence alone does not automatically establish drug toxicity; exposure, biological plausibility, alternative diagnoses, and the course of the condition must be assessed.
Among exposures with well-established causal relationships, anthracyclines may directly injure the myocardium; anti-HER2 treatments interfere with signaling required for cardiomyocyte adaptation; VEGF pathway inhibitors disrupt vascular homeostasis; and immune checkpoint inhibitors may trigger an immune response directed against cardiac structures. Radiation therapy involving the heart may simultaneously affect coronary arteries, microcirculation, myocardium, valves, pericardium, and the conduction system. For molecularly targeted therapies, tumor selectivity does not guarantee exclusive selectivity: many anticancer targets also participate in cardiovascular physiology.
Susceptibility depends on the cardiovascular reserve present before exposure. Heart failure, cardiomyopathy, coronary artery disease, significant valvular disease, hypertension, diabetes, and kidney disease may increase the likelihood or consequences of injury. Older age, frailty, smoking, obesity, and physical inactivity add vulnerability; in patients treated during childhood, the long remaining lifespan during which injury may become apparent is also important. These conditions do not all cause the same form of toxicity, and their relative importance varies by drug. For example, uncontrolled blood pressure is particularly relevant before starting a VEGF inhibitor, whereas previous anthracycline exposure is decisive when assessing subsequent anti-HER2 therapy.
Cumulative dose and combinations of treatments further modify risk. Anthracycline-induced cardiomyopathy has an exposure–response relationship but may also occur at doses below those historically considered high. For radiation, relevant factors include the dose actually delivered to the heart and its substructures, spatial distribution, fractionation, and concurrent exposures. It is incorrect to equate the dose prescribed to the tumor with the cardiac dose or to assume that a single threshold can absolutely distinguish safety from danger.
Anthracycline-induced myocardial injury involves alterations in DNA, mitochondrial dysfunction, oxidative stress, and loss of cardiomyocytes. The role of topoisomerase IIβ has been demonstrated in experimental models in which selective deletion of this enzyme in cardiomyocytes protected against doxorubicin-induced damage. Reduced capacity to produce energy and disruption of the systems regulating calcium and contraction may precede a measurable decline in overall function. When cell loss and remodeling exceed compensatory capacity, contractile reserve falls and filling pressures may rise.
A different mechanism characterizes anti-HER2-related dysfunction. Neuregulin–ErbB signaling contributes to cardiomyocyte survival and stress responses; interference with it may leave the heart less able to tolerate previous or concurrent injury. Functional recovery is common but not universal. The traditional distinction between invariably irreversible anthracycline toxicity and invariably reversible trastuzumab toxicity is therefore inadequate: the chance of recovery also depends on the extent of injury, prompt recognition, and cardiac treatment.
Within the vasculature, VEGF inhibition reduces proangiogenic and vasodilatory signaling, promotes endothelial dysfunction, and may increase peripheral resistance. Increased afterload raises ventricular wall stress and may precipitate heart failure in a vulnerable heart. Other treatments promote coronary spasm, endothelial injury, thrombosis, or accelerated atherosclerosis. Coronary ischemia may therefore result from different functional or structural mechanisms that call for distinct preventive and therapeutic strategies.
Immunological therapies have introduced additional phenotypes. In immunotherapy-associated myocarditis, removal of restraints on the immune response may disrupt tolerance of the myocardium and conduction system. With CAR-T cells, by contrast, many cardiovascular complications develop in the setting of cytokine release syndrome: systemic inflammation, vasodilation, increased capillary permeability, hypotension, and tachycardia simultaneously alter preload, afterload, and metabolic demand. Hemodynamic deterioration does not necessarily indicate myocarditis and may involve several mechanisms.
The malignancy itself may have cardiovascular consequences through infiltration, compression, mediator secretion, and activation of coagulation. Cancer-associated thromboembolism arises from interactions among tumor factors, host responses, immobility, procedures, and treatment. Neoplastic pericardial disease may impair cardiac filling through fluid accumulation or infiltration of the pericardial layers. These conditions are distinct from treatment toxicity, even when identified during anticancer therapy.
Over time, reduced functional myocardial mass, fibrosis, microvascular rarefaction, and comorbidities may converge on the same hemodynamic outcome. A dilated ventricle may lose its ejection capacity; a stiff ventricle may require high pressures to fill despite a preserved ejection fraction. Valvular and pericardial diseases add mechanical loads or constraints, while arrhythmias and dysautonomia may further reduce cardiac output. These interacting effects explain why cardio-oncological assessment must encompass the entire cardiovascular system rather than a single echocardiographic measurement.
The clinical assessment begins by reconstructing the oncological and cardiovascular history. Essential information includes cancer type and stage, treatment goals, drugs already administered or planned, available cumulative doses, radiation fields, stem cell transplantation, and any previous toxicity episodes. Remote history remains relevant even after decades: mediastinal irradiation during adolescence may matter clinically when an adult develops a murmur, angina, or dyspnea. Known heart disease, risk factors, family history of cardiomyopathy or sudden death, and all medications—including over-the-counter products and supplements—must be recorded alongside this information.
The timing of symptoms should be related to treatment cycles, infusions, and regimen changes without treating this association as proof of causation. Pain during a fluoropyrimidine infusion raises a different question from slowly progressive dyspnea years after radiation therapy. In patients receiving immunotherapy, new conduction abnormalities or muscle weakness may warrant urgent attention even without congestion. Comparison with functional capacity before cancer treatment is often more informative than a nonspecific report of fatigue.
Dyspnea is characterized by its onset, relation to exertion, lying supine, nocturnal awakening, cough, and weight changes. Orthopnea, paroxysmal nocturnal dyspnea, and increasing edema make heart failure plausible, but a patient with cancer may simultaneously have anemia, pulmonary embolism, infection, pleural effusion, pulmonary toxicity, or tumor progression. Increased respiratory rate or a rapid decline in exercise tolerance should not be attributed solely to deconditioning without assessment proportionate to severity and context.
Chest pain requires evaluation of location, duration, radiation, triggers, and associated symptoms. Pressure-like pain, onset at rest, or a relation to exertion suggests ischemia; a relation to inspiration and posture may suggest pericardial involvement but is not diagnostic. Coronary disease and altered pain perception may coexist after thoracic irradiation, producing less typical symptoms. Sudden pain accompanied by dyspnea, hypoxemia, or syncope also calls for consideration of a thromboembolic complication.
Palpitations, an irregular pulse, presyncope, and syncope suggest rhythm disturbances, without ruling out hypotension, hypovolemia, anemia, or autonomic abnormalities. It is important to establish whether the event occurred during exertion, at rest, after standing, or around the time a new drug was taken. Syncope may reflect ventricular arrhythmia associated with QT prolongation, but it may also result from atrioventricular block in myocarditis. In these settings, a brief event with spontaneous recovery is not necessarily of lesser clinical significance.
History-taking must include extracardiac symptoms that change interpretation of the presentation. Fever and chills suggest infection or a systemic reaction; diarrhea and vomiting may cause hypovolemia and electrolyte loss; unilateral limb swelling may indicate thrombosis. During immunotherapy, myalgia, dysphagia, diplopia, or ptosis raise concern for multisystem immune-mediated toxicity. Reduced food intake, muscle wasting, and frailty influence both clinical presentation and tolerance of cardiovascular treatment.
Physical examination begins with general condition and hemodynamic stability: level of consciousness, temperature, respiratory rate, oxygen saturation, blood pressure, and heart rate. Weight should be compared with previous measurements, distinguishing fluid retention from loss of body mass. Blood pressure requires correct measurement technique and, when indicated, orthostatic assessment; a sustained rise during antiangiogenic treatment may precede other signs of injury. Pulse examination looks for irregularity, reduced amplitude, and asymmetry, while peripheral temperature and perfusion help identify inadequate cardiac output.
Assessment then includes jugular venous pressure, cardiac and pulmonary auscultation, and examination for edema and signs of systemic congestion. Crackles, jugular venous distension, and an S3 gallop support heart failure but may be absent early; a murmur may indicate pre-existing valvular disease or late radiation-related disease. When pericardial effusion is suspected, tachycardia, hypotension, and signs of impaired filling require urgent echocardiography. Examination of the swollen limb and venous access sites may provide further evidence of thrombosis, infection, or obstruction.
A clinically important proportion of patients remain asymptomatic when the first imaging or laboratory abnormalities appear. A normal examination therefore does not replace scheduled surveillance in people exposed to treatment that carries cardiovascular risk. Conversely, a new symptom changes the care pathway and brings investigations forward from the planned schedule. Persistent chest pain, syncope, dyspnea at rest, hypotension, or rapid overall deterioration require urgent assessment, with stabilization taking priority over complete identification of the cause.
There are no diagnostic criteria for cardio-oncology itself, because it is a field of care rather than a single disease. Under the approach set out in ESC guidelines, the pathway should first establish cardiovascular status, estimate treatment-associated risk, and arrange monitoring capable of detecting the expected phenotype. A high-risk classification identifies the need for closer attention and preventive measures; it is not a diagnosis of cardiotoxicity and, by itself, is not sufficient reason to withhold an effective treatment.
HFA-ICOS tools integrate pre-existing cardiovascular disease, risk factors, baseline findings, and cancer treatment exposures. They are specific to treatment groups and classify risk as low, moderate, high, or very high. Their value lies in organizing assessment and intensity of care, but predictive performance is not consistent across all populations and requires further validation. They must not be confused with atherosclerotic risk scores developed for the general population, applied indiscriminately to every drug, or used to attribute the cause of an event retrospectively.
A 12-lead ECG documents rhythm, conduction, possible ischemic changes, and the corrected QT interval. A pre-treatment tracing makes it possible to recognize new changes and correctly interpret QT prolongation or bundle branch block. A normal ECG does not exclude ventricular dysfunction, coronary artery disease, or myocarditis. In patients with intermittent palpitations, syncope, or documented abnormalities, prolonged rhythm monitoring is selected according to episode frequency and the likelihood of an arrhythmic cause.
General blood tests include, depending on the context, complete blood count, kidney function, electrolytes, blood glucose or glycated hemoglobin, and lipid profile. These are not merely ancillary tests: anemia, renal impairment, and potassium or magnesium disturbances can cause symptoms, alter arrhythmia risk, and restrict cardiovascular treatment. Thyroid function is relevant in the presence of arrhythmias, compatible symptoms, or therapies that may affect it. In frail patients, nutritional status and liver function help interpret edema, drug tolerance, and bleeding risk.
Troponin and natriuretic peptides answer different clinical questions. Troponin indicates myocardial injury; BNP and NT-proBNP mainly reflect myocardial wall stress and contribute to heart failure assessment. If they are used for surveillance, a baseline measurement is needed to interpret changes. Comparisons must account for the assay method, renal function, rhythm, acute conditions, and sample timing relative to therapy. A single abnormal value does not establish a specific drug-related cause or, on its own, indicate which anticancer treatment should be stopped.
Echocardiography is the principal imaging test for assessing ventricular function, cardiac chambers, valves, the pericardium, and probable abnormalities in filling pressures. During treatments that carry a risk of ventricular dysfunction, reproducible measurement of ejection fraction and, where available, global longitudinal strain provides the basis for longitudinal comparison. Three-dimensional acquisitions are helpful when technically adequate; using the same method, the same strain-analysis platform, and comparable hemodynamic conditions reduces the risk of mistaking measurement variability for disease.
Global longitudinal strain may worsen before an evident fall in ejection fraction but is influenced by image quality, blood pressure, loading conditions, and software. It should be interpreted alongside symptoms, biomarkers, and volumetric measurements. The distinction between a relative reduction in strain and an absolute change in ejection fraction is essential: these are different measurements and cannot be used interchangeably. A doubtful or discordant change calls for technical review and, when needed, confirmation before decisions that could compromise cancer treatment.
Cardiac magnetic resonance imaging provides further assessment when echocardiography is unreliable or myocardial tissue characterization is required. It accurately measures volumes and function and may reveal edema, fibrosis, or infiltration, helping distinguish ischemia, myocarditis, and other cardiomyopathies. It is not used indiscriminately in every patient: the choice must address a specific clinical question. Endomyocardial biopsy is reserved for selected circumstances in which histological diagnosis may change management, particularly in complex or rapidly evolving presentations.
Vascular investigations depend on the clinical presentation. Chest pain and ischemic changes require the appropriate coronary syndrome pathway; venous ultrasonography and CT pulmonary angiography are used when thrombosis or embolism is suspected. In previously irradiated patients, the decision on whether to screen for subclinical coronary disease should take account of dose, time since exposure, and overall risk. Radiation-induced heart disease may require a multimodality approach because no single technique adequately describes the coronary arteries, valves, pericardium, and myocardium.
The investigations should culminate in a specific clinical diagnosis: heart failure, asymptomatic ventricular dysfunction, myocarditis, coronary syndrome, arrhythmia, hypertension, thromboembolism, or pericardial disease. Subsequent attribution of cause considers the temporal relationship, cumulative exposure, known treatment-related phenotype, and competing causes. Monitoring is then updated, with more frequent assessments during instability and less frequent ones after stabilization. A useful plan also specifies who receives the results, what changes prompt reassessment, and how decisions are coordinated with the oncologist.
Management is based on a multidisciplinary balance between cardiovascular risk and cancer treatment benefit. The assessment includes the potential for cure, disease control, treatment alternatives, risk of progression during interruption, and likelihood of cardiac recovery. The same abnormality may have different implications during adjuvant treatment, in an aggressive cancer with no equivalent alternatives, or in advanced disease when the patient's priority is symptom control. Shared decision-making requires a concrete explanation of benefits and risks, avoiding automatic decisions based on a single number.
Prevention begins with appropriate treatment of existing diseases. Blood pressure, lipids, diabetes, smoking, and physical inactivity should be addressed before and during cancer therapy, in keeping with their urgency. Adapted physical activity, nutritional support, and preservation of muscle mass may improve functional capacity and tolerance of the cancer care pathway. It would be incorrect to promise that these measures eliminate a particular toxicity; their value is in reducing cardiovascular vulnerability and disability, complementing rather than replacing indicated oncological and cardiological interventions.
The choice of anticancer regimen can help protect the heart when alternatives with adequate efficacy exist. Reducing cardiac radiation exposure, using techniques that spare healthy structures, and considering less cardiotoxic formulations or schedules are oncological decisions that should be made alongside cardiovascular risk stratification. Dexrazoxane has a specific role in protecting against anthracycline toxicity in selected settings; its indication depends on risk, the need to continue anthracycline treatment, and the regulatory context. It does not provide general protection against all treatment classes.
Preventive use of cardiovascular medications requires critical appraisal of the evidence. ACE inhibitors, angiotensin receptor blockers, beta-blockers, and statins have been studied with varying results, often using intermediate outcomes such as ejection fraction, strain, or biomarkers. Guidelines and consensus documents consider selective strategies in high-risk patients, but there is no evidence that a drug combination should be routinely prescribed to everyone receiving chemotherapy. An independent cardiovascular indication remains valid, but must be distinguished from prophylaxis specifically intended to prevent cardiotoxicity.
When heart failure with reduced ejection fraction is present, treatment follows cardiology guideline principles adapted to blood pressure, renal function, electrolytes, and tolerance. It includes disease-modifying medications, control of congestion, and correction of precipitating factors. Cancer treatment introduces specific constraints: vomiting, diarrhea, poor fluid intake, infections, and nephrotoxicity can rapidly alter the clinical balance. Surveillance must therefore accompany treatment initiation and dose titration rather than ending with an initial prescription.
Whether cancer therapy can continue during cardiac dysfunction also depends on the drug class. In the small prospective SAFE-HEaRt study, 27 of 30 evaluable patients, selected because they were asymptomatic with an ejection fraction of 40–49%, completed their planned anti-HER2 treatment while receiving cardiac treatment and close monitoring. This finding supports individualized management in specialist care but does not justify extending the same approach to unstable heart failure, myocarditis, or other exposures. Mild, manageable toxicity may be compatible with continuation; a potentially life-threatening complication requires different priorities.
Emergencies are treated according to their underlying mechanism. Clinically probable immune-mediated myocarditis requires prompt interruption of immunotherapy, monitoring, and appropriate immunosuppressive treatment; a coronary syndrome requires assessment and reperfusion when indicated; tamponade requires drainage. In thromboembolism, anticoagulant selection must integrate tumor location, bleeding risk, platelet count, renal function, absorption, and interactions. Cancer changes the therapeutic balance but does not diminish the importance of cardiovascular emergencies.
Medication reconciliation is an integral component of care. Oral antineoplastic agents, antiarrhythmics, anticoagulants, antimicrobials, and supportive medications may share metabolic pathways or have additive effects on QT, blood pressure, and bleeding. Checking oncological prescriptions alone is insufficient: all medicines taken must be identified and the review repeated whenever the regimen changes. Collaboration with a clinical pharmacist is particularly helpful with complex combinations and in patients with renal or hepatic impairment.
At the end of treatment, patients should receive a summary of exposures, any toxicities, and a plan for follow-up assessments. Long-term surveillance is proportionate to anthracycline dose, cardiac radiation exposure, abnormalities identified, and persistent risk factors. No single schedule has been proven optimal for all survivors. Recommendations provide for initial and subsequent assessments tailored to risk; patients with documented heart disease continue disease-specific follow-up, while those at lower risk do not automatically require the same number of tests.
Survivors of childhood and adolescent cancers require particular continuity of care during transition to adult services. Remote exposures may become important with aging, the onset of hypertension, or pregnancy. In women previously treated with potentially cardiotoxic therapies, reproductive planning may warrant cardiovascular reassessment, particularly if abnormalities or a history of dysfunction exist. Many symptom-free years do not erase the importance of the treatment history.
Prognosis is determined by the interaction between cancer and cardiovascular disease trajectories. Dysfunction detected early may recover substantially, whereas advanced fibrosis, persistent ischemia, severe valvular disease, or repeated episodes of heart failure may leave lasting risk. Recovery of ejection fraction does not necessarily establish complete restoration of myocardial integrity. In patients with advanced disease, palliative care and cardiological treatment may be integrated to relieve dyspnea, congestion, and suffering, matching the intensity of care to shared goals.
There is no single ranking of complications that applies to all therapies. Ventricular dysfunction is a central concern with anthracycline or anti-HER2 regimens; hypertension is frequent with many antiangiogenic agents; certain immunotherapies carry a risk of rarer but highly severe events. Clinical significance reflects the interplay of probability, speed of onset, reversibility, and consequences. Even an uncommon complication may warrant priority when delayed diagnosis carries a high risk.
Heart failure may cause congestion, reduced functional capacity, renal impairment, and repeated hospitalizations. When cardiac output becomes inadequate, hypoperfusion may affect the kidneys, liver, and nervous system, progressing to shock. Reduced food intake, cancer cachexia, and congestion together may make recovery harder. These consequences reinforce one another: unstable renal function limits treatment, while persistent congestion further worsens organ function.
Arrhythmias may cause palpitations, syncope, hemodynamic deterioration, or sudden death. Atrial fibrillation adds an embolic risk that must be weighed against bleeding, thrombocytopenia, and invasive procedures. QT prolongation can promote torsades de pointes, especially when bradycardia, hypokalemia, hypomagnesemia, and multiple drugs affecting repolarization coexist. Conduction disorders in myocarditis may progress rapidly even when systolic function appears preserved.
Vascular events include myocardial infarction, stroke, peripheral ischemia, and venous thromboembolism. Thrombosis may be promoted by the tumor and further influenced by medications, catheters, or immobility; antithrombotic treatment may itself be complicated by hemorrhage. Consequences extend beyond the affected organ: procedures may need to be postponed, doses adjusted, or cancer therapy temporarily interrupted. Uncontrolled treatment-induced hypertension can contribute to these events and precipitate heart failure or kidney injury.
Late radiation injury may combine coronary disease, valvular stenosis or regurgitation, constrictive pericarditis, and conduction abnormalities. Coexisting lesions complicate attribution of symptoms and may increase the risk of surgical or interventional procedures. A neoplastic effusion may instead progress to tamponade through increasing intrapericardial pressure that impedes filling; severity depends on the rate of fluid accumulation, not only on its volume.
One overarching consequence is loss of treatment continuity. Toxicity may require dose reduction or interruption of anticancer therapy, but an unnecessary pause caused by misinterpretation of a finding can also have oncological consequences. Preventing complications therefore entails high-quality measurements, timely diagnosis, and coordinated decisions. In long-term survivors, an adverse outcome may be persistent cardiovascular disability; continued care seeks to preserve independence, ability to work, and quality of life alongside survival.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.